Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas

Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard Lutes, Andy Chi, Stefano Pileri

Research output: Contribution to journalArticlepeer-review

Abstract

Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory disease. Systemic treatment for relapsed/refractory CTCL has historically relied on chemotherapies and interferons, and while active, responses are often short-lived. Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Although response rates are typically

Original languageEnglish
Pages (from-to)228-240
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume99
DOIs
Publication statusPublished - Mar 1 2016

Keywords

  • Bexarotene
  • Brentuximab vedotin
  • Cutaneous T-cell lymphoma
  • Mycosis fungoides
  • Romidepsin
  • Sézary syndrome
  • Vorinostat

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas'. Together they form a unique fingerprint.

Cite this